News & Updates

First-line treatment with ivonescimab significantly improves overall survival (OS) in patients with PD-L1-positive (PD-L1+) locally advanced or metastatic nonsmall cell lung cancer (NSCLC) compared with pembrolizumab, according to a prespecified interim analysis of the phase III HARMONi-2 trial presented at WCLC 2026.

Type 2 diabetes (T2D) patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) concomitantly appear to be at lower risk of dementia compared with those receiving a GLP-1 RA or SGLT-2i monotherapy, according to a study.

First-line treatment with carboplatin/paclitaxel (CP), with or without radiotherapy, is not associated with improvements in survival among patients with anaplastic thyroid cancer (ATC), as shown in a study.

Initiating supplementation with calcium before or during pregnancy falls short of reducing the risk of pre-eclampsia, according to an individual participant data (IPD) meta-analysis.

A recent study has shown the feasibility of 24-week abrocitinib tapering in well-responding patients with moderate-to-severe atopic dermatitis (AD), reducing treatment burden without compromising efficacy.